Document Detail

Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature.
MedLine Citation:
PMID:  20676778     Owner:  NLM     Status:  MEDLINE    
The aim of the study is to assess the rate of any potential adverse effects on women who became pregnant under cabergoline (CAB) treatment and to evaluate any effects on the embryo-fetal development and on children who were born from mothers exposed to CAB in early weeks of gestation. Observational, retrospective and multicenter study on 103 pregnancies in 90 women with hyperprolactinemia. All patients were under CAB at conception. Serum prolactin at baseline was between 30 and 1921 ng/ml. Duration of therapy before pregnancy ranged from 1 to 120 months and doses ranged from 0.125 to 5 mg/week. Fetal exposure ranged from 3 to 25 weeks, 96.9% of patients received CAB during the first trimester of pregnancy and the rest until the second one. No significant complications during pregnancy were found. Seven women (7.2%) had spontaneous abortions. Preterm deliveries were recorded in eight (8.8%), only one with low weight for gestational age. Neonatal abnormalities were observed in 3 (3.6%): 1 major (Down syndrome) and 2 minor malformations (umbilical and inguinal hernia). We were able to asses the children's development in 61. Two had epilepsy and two had Pervasive Developmental Disorder (PDD). No significantly higher frequency of complications was found in pregnancies and/or offspring exposed to CAB than in the normal population. We registered 2 abnormalities in the development of the children: epilepsy and PDD. Larger series of patients are needed to assess the safety of this drug during pregnancy.
Graciela Stalldecker; María Susana Mallea-Gil; Mirtha Guitelman; Analía Alfieri; María Carolina Ballarino; Laura Boero; Alberto Chervin; Karina Danilowicz; Sabrina Diez; Patricia Fainstein-Day; Natalia García-Basavilbaso; Mariela Glerean; Viviana Gollan; Débora Katz; Mónica Graciela Loto; Marcos Manavela; Amelia Susana Rogozinski; Marisa Servidio; Nicolás Marcelo Vitale
Related Documents :
21309498 - Effect of number of pregnancies on bone mineral density.
17454318 - Effect of maternal asthma and gestational asthma therapy on fetal growth.
6845218 - Prospective study of suspected associations between certain drugs administered during e...
19794358 - Pregnancy and atypical antipsychotics.
8532258 - Cost-effectiveness of in vitro fertilization.
10624508 - Sperm extracted and cryopreserved from testes several hours after death results in preg...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pituitary     Volume:  13     ISSN:  1573-7403     ISO Abbreviation:  Pituitary     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-10-26     Completed Date:  2011-02-07     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9814578     Medline TA:  Pituitary     Country:  United States    
Other Details:
Languages:  eng     Pagination:  345-50     Citation Subset:  IM    
Departamento de Neuroendocrinología, Sociedad Argentina de Endocrinología y Metabolismo, Diaz Velez 3889, 1200 Buenos Aires, Argentina,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cross-Sectional Studies
Dopamine Agonists / therapeutic use*
Ergolines / adverse effects,  therapeutic use*
Gestational Age
Hyperprolactinemia / drug therapy*
Middle Aged
Pregnancy Complications / chemically induced*
Premature Birth / chemically induced
Prolactin / blood
Retrospective Studies
Young Adult
Reg. No./Substance:
0/Dopamine Agonists; 0/Ergolines; 9002-62-4/Prolactin; LL60K9J05T/cabergoline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lymphocytic hypophysitis in a patient presenting with sequential episodes of optic neuritis.
Next Document:  Sleep disorders among undergraduate students in Southern Brazil.